Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1

Lancet

Volumn 351, Issue 9099, 1998, Pages 316-321

  Verhoog, L C ^a   Brekelmans, C T M ^a   Seynaeve, C ^a   Van Den Bosch, L M C ^a   Dahmen, G ^a   Van Geel, A N ^a   Tilanus Linthorst, M M A ^a   Bartels, C C M ^a   Wagner, A ^b   Van Den Ouweland, A ^b   Devilee, P ^c   Meijers Heijboer, E J ^b   Klijn, J G M ^a,d  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GENETICS; CANCER RECURRENCE; CANCER SURVIVAL; FAMILIAL CANCER; FEMALE; GENE MUTATION; GERM LINE; HISTOPATHOLOGY; HUMAN; ONCOGENE; PRIORITY JOURNAL; TUMOR VOLUME;

EID: 17344392776     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)07065-7     Document Type: Article

References (30)

1. 1 Easton DF, Ford D, Bishop DT, and the Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 1995; 56: 265-71.
2. 2 Hall JM, Lee MK, Newman B, et al. Linkage of early onset familial breast cancer to chromosome 17q21. Science 1990; 250: 1684-89.
3. 3 Miki Y, Swensen J, Shattuck Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71.
4. 4 Cornelis R, Vasen H, Meijers-Heijboer H, et al. Age at diagnosis as an indicator of eligibility for BRCA1 DNA testing in familial breast cancer. Hum Genet 1995; 95: 539-44.
5. 5 Ford D, Easton DF, Bishop DT, et al. Risk of cancer in BRCA1-mutation carriers. Lancet 1994; 343: 692-95.
6. 6 Lynch HT, Marcus JN, Watson P, Conway T, Lynch J, Page D. Increased proliferation in hereditary breast cancer. Proc ASCO 1993; 12: 82 (abstr 128).
7. 7 Lynch HT, Marcus JN, Watson P, Page D. Distinctive clinicopathological features of BRCA1 linked hereditary breast cancer. Proc ASCO 1994; 13: 56 (abstr 27).
8. 8 Marcus JN, Watson P, Page DL, et al. Hereditary breast cancer: pathobiology, prognosis and BRCA1 and BRCA2 gene linkage. Cancer 1996; 77: 697-709.
9. 9 Jacquemier J, Eisinger F, Birnbaum D, Sobol H. Histoprognostic grade in BRCA1-associated breast cancer. Lancet 1995; 345: 1503.
10. 10 Eisinger F, Stoppa-Lyonnet D, Longy M, et al. Germline mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 1996; 56: 471-74.
11. 11 Sobol H, Stoppa-Lyonnet D, Bressac-de-Paillerets B, et al. Truncation at conserved terminal regions of BRCA1 protein is associated with highly proliferating hereditary breast cancers. Cancer Res 1996; 56: 3216-19.
12. 12 Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997; 349: 1505-10.
13. 13 Johannsson OT, Idvall I, Anderson C, et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997; 33: 362-71.
14. 14 Klijn JGM, Berns PMJJ, Foekens JA. Prognostic factors and response to therapy in breast cancer. Cancer Surv 1993; 18: 165-98.
15. 15 De La Rochefordiere A, Asselain B, Campana F, et al. Age as a prognostic factor in premenopausal breast carcinoma. Lancet 1993; 341: 1039-43.
16. 16 Porter DE, Cohen BB, Wallace MR, et al. Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21. Br J Surg 1994; 81: 1512-15.
17. 17 Lynch HT, Albano WA, Recabaren JA, Fain PR, Lynch PM. Survival in hereditary breast and colon cancer. JAMA 1981; 246: 1197.
18. 18 Wobbes TH, van de Wiel MP, van der Sluis RF, Theeuwes AGM. The effect of familiality on clinical presentation and survival in mammary carcinoma. Eur J Surg Oncol 1987; 13: 119-21.
19. 19 Lees AW, Jenkins HJ, May CL, Cherian G, Lam EWH, Hanson J. Risk factors and 10-year breast cancer survival in northern Alberta. Breast Cancer Res Treat 1989; 13: 143-51.
20. 20 Malone KE, Daling JR, Weiss NS, McKnight B, White E, Voigt LF. Family history and survival of young women with invasive breast carcinoma. Cancer 1996; 78: 1417-25.
21. 21 Henderson IC, Patek AJ. Are breast cancers in young women qualitatively distinct? Lancet 1997; 349: 1488-89.
22. 22 Hogervorst FBL, Cornelis RS, Bout M, et al. Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet 1995; 10: 208-12.
23. 23 Peelen T, van Vliet M, Petrij-Bosch A, et al. A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet 1997; 60: 1041-49.
24. 24 Petrij-Bosch A, Peelen T, van Vliet M, et al. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer families. Nat Genet 1997; 17: 341-45.
25. 25 Foekens JA, Portengen H, van Putten WLJ, et al. Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res 1989; 49: 5823-28.
26. 26 Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980.
27. 27 Coebergh JWW, van der Heijden LH, Janssen-Heijen MLG, eds. Cancer incidence and survival in the Southeast of the Netherlands 1955-1994. Comprehensive Cancer Centre South, Eindhoven 1995.
28. 28 Klijn JGM. Should prophylactic surgery be used in women with a higher risk of breast cancer? Eur J Cancer 1997; 33: 2149-54.
29. 29 Jacquemier J, Eisinger F, Guinebretiere J-M, Stoppa-Lyonnet D, Sobol H. Intraductal component and BRCA1-associated breast cancer. Lancet 1996; 348: 1098.
30. 30 Solin LJ, Haas J, Schulte DJ. Breast cancer in young women: the University of Pennsylvania experience - breast cancer: advances in biology and therapeutics. John Libbey Eurotext 1996: 351-54.